Cited by 448Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Open access

Douillard, Jean-Yves, Ostoros, Gyula, Cobo, Manuel, Ciuleanu, Tudor, Cole, Rebecca, McWalter, Gael, Walker, Jill, Dearden, Simon, Webster, Alan, Milenkova, Tsveta, McCormack, Rose·2014·Journal of Thoracic Oncology

DOI 10.1097/jto.0000000000000263PMC PMC4224589

Open this paper in CoChat — free account Open PDF

Abstract

INTRODUCTION: In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (previously published). Here, we report EGFR mutation analyses of plasma-derived, circulating-free tumor DNA. METHODS: Mandatory tumor and duplicate plasma (1 and 2) baseline samples were collected (all screened patients; n = 1060). Preplanned, exploratory analyses included EGFR mutation (and subtype) status of tumor versus plasma and between plasma samples. Post hoc, exploratory analyses included efficacy by tumor and plasma EGFR mutation (and subtype) status. RESULTS: Available baseline tumor samples were 1033 of 1060 (118 positive of 859 mutation status known; mutation frequency, 13.7%). Available plasma 1 samples were 803 of 1060 (82 positive of 784 mutation status known; mutation frequency, 10.5%). Mutation status concordance between 652 matched tumor and plasma 1 samples was 94.3% (95% confidence interval [CI], 92.3-96.0) (comparable for mutation subtypes); test sensitivity was 65.7% (95% CI, 55.8-74.7); and test specificity was 99.8% (95% CI, 99.0-100.0). Twelve patients of unknown tumor mutation status were subsequently identified as plasma mutation-positive. Available plasma 2 samples were 803 of 1060 (65 positive of 224 mutation status-evaluable and -known). Mutation status concordance between 224 matched duplicate plasma 1 and 2 samples was 96.9% (95% CI, 93.7-98.7). Objective response rates are as follows: mutation-positive tumor, 70% (95% CI, 60.5-77.7); mutation-positive tumor and plasma 1, 76.9% (95% CI, 65.4-85.5); and mutation-positive tumor and mutation-negative plasma 1, 59.5% (95% CI, 43.5-73.7). Median progression-free survival (months) was 9.7 (95% CI, 8.5-11.0; 61 events) for mutation-positive tumor and 10.2 (95% CI, 8.5-12.5; 36 events) for mutation-positive tumor and plasma 1. CONCLUSION: The high concordance, specificity, and sensitivity demonstrate that EGFR mutation status can be accurately assessed using circulating-free tumor DNA. Although encouraging and suggesting that plasma is a suitable substitute for mutation analysis, tumor tissue should remain the preferred sample type when available.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0000000000000263

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,575
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Kim, E. S., Hirsh, V., Mok, T. S. K., Socinski, M. A., Gervais, R., Wu, Y.-L. L. C., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,241
Self-citation
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Oxnard, G. R., Paweletz, C. P., Kuang, Y., Mach, S. L., O'Connell, A., Messineo, M. M., Luke, J. J., Butaney, M., Kirschmeier, P., Jackman, D. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2482 · Cited by 786

Show all 28 references

Research works printed but not linked: 2

Reck, 2013, Investigating the utility of plasma-derived circulating-free DNA for the detection of EGFR mutations in European and Japanese patients with advanced NSCLC: ASSESS study design, J Thorac Oncol, S483
Han, 2013, A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with NSCLC of adenocarcinoma and non-adenocarcinoma histology: IGNITE study design, J Thorac Oncol, 8, S1098

Sorted by citations

Items 201–300 of 448

Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer
Voigt, W., Manegold, C., Pilz, L. R., Wu, Y.-L. L. C., Müllauer, L., Pirker, R., Filipits, M., Nikliński, J., Petruzelka, L. B., & Prosch, H. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000598 · Cited by 29
Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients
Porter, A., Natsuhara, M., Daniels, G. A., Patel, S. P., Sacco, A. G., Bykowski, J., Banks, K. C., & Cohen, E. E. W. (2020) · Translational Cancer Research · doi:10.21037/tcr.2019.12.70 · Cited by 28
Advances in Circulating Tumor DNA Analysis
Perakis, S. O., Auer, M., Belic, J., & Heitzer, E. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.005 · Cited by 28
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
Yu, H. A., Spira, A. I., Horn, L., Weiss, J. M., West, H., Giaccone, G., Evans, T. L., Kelly, R. J., Desai, B., Krivoshik, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1447 · Cited by 27
Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
Heydt, C., Michels, S. Y. F., Thress, K. S., Bergner, S., Wolf, J., & Buettner, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24624 · Cited by 27
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS
Arriola, E., Lario, A. P., García-Gomez, R., Taín, P. D., Constenla, M., Girón, C. G., Márquez, G., Reck, M., & López-Vivanco, G. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1855-y · Cited by 27
Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer
Gray, J. E., Thompson, J. C., Carpenter, E. L., Elkhouly, E., & Aggarwal, C. (2021) · The Oncologist · doi:10.1002/onco.13889 · Cited by 28
Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer
Guo, K. X., Zhang, Z., Han, L., Han, J. Y., Wang, J., Zhou, Y., Tong, L., Liu, H., Li, X., & Yan, X. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s94297 · Cited by 26
Feasibility of Cell-Free Circulating Tumor DNA Testing for Lung Cancer
Santarpía, M., Karachaliou, N., González‐Cao, M., Altavilla, G., Giovannetti, E., & Rosell, R. (2016) · Biomarkers in Medicine · doi:10.2217/bmm.16.6 · Cited by 26
Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey
ASBL, O. B. O. I. P., Deans, Z. C., Williams, H. L., Dequeker, E. M. C., Keppens, C., Normanno, N., Schuuring, E. M. D., Patton, S. J., Cheetham, M. H., Butler, R., et al. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2222-z · Cited by 26
Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
Qvick, A., Stenmark, B., Carlsson, J., Isaksson, J., Karlsson, C., & Helenius, G. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00331-1 · Cited by 27
Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series
Tchekmedyian, N., Mudad, R., Blanco, F. F., Raymond, V. M., Garst, J. H., Erlander, M. G., Haura, E. B., & Berz, D. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.010 · Cited by 26
Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma
Taylor, C., Chacko, S. M., Davey, M., Lacroix, J., MacPherson, A., Finn, N., Wajnberg, G., Ghosh, A., Crapoulet, N., Lewis, S. M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239083 · Cited by 25
Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
Kim, C. G., Shim, H. S., Hong, M. H., Cha, Y. J., Heo, S. J., Park, H. S., Kim, J. H., Lee, J. G., Lee, C. Y., Cho, B. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17786 · Cited by 24
Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy
Soria-Comes, T., Abril, V. P., Ureste, M. M., Guerola, M. T., & Maestu, I. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00628-x · Cited by 23
Role of Next-Generation Sequencing Technologies in Personalized Medicine
Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Viale, G., Trapani, D., Duso, B. A., & Curigliano, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-27994-3_8 · Cited by 30
Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study
Tomasini, P., Barlési, F., Gilles, S., Nanni‐Metellus, I., Soffietti, R., Denicolaï, E., Pellegrino, E., Bialecki, E., Ouafik, L., & Métellus, P. (2020) · Oncotarget · doi:10.18632/oncotarget.27837 · Cited by 23
Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer
Metzenmacher, M., Hegedűs, B., Förster, J., Schramm, A. R., Horn, P., Klein, C. A., Bielefeld, N., Plönes, T., Aigner, C., Theegarten, D., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101279 · Cited by 24
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
Canale, M., Pasini, L., Bronte, G., Delmonte, A., Cravero, P., Crinò, L., & Ulivi, P. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.15 · Cited by 24
The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations
Tan, J., Hu, C., Deng, P., Wan, R., Cao, L., Li, M., Yang, H., Gu, Q., An, J., & Jiang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646577 · Cited by 23
Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer
Kim, E. J.-H., Feldman, R. A., & Wistuba, I. I. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.08.001 · Cited by 23
Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician
Singh, A. P., Cheng, H., Guo, X., Levy, B. P., & Halmos, B. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00054 · Cited by 23
Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients
Meng, P., Wei, J., Geng, Y., Chen, S., Terpstra, M. M., Huang, Q., Zhang, Q., Su, Z., Yu, W., Su, M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6025-2 · Cited by 23
EGFR inhibition in NSCLC: New findings…. and opened questions?
Passiglia, F., Listì, A., Castiglia, M., Perez, A., Rizzo, S., Bazan, V., & Russo, A. D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.009 · Cited by 22
Chasing ctDNA in Patients With Sarcoma
Coombs, C. C., Dickherber, T., & Crompton, B. D. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280749 · Cited by 23
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring
Nesvet, J. C., Antilla, K. A., Pancirer, D., Lozano, A. X., Preiss, J. S., Ma, W., Fu, A., Park, S.-M., Gambhir, S. S., Fan, A. C., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa307 · Cited by 22
A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting
Sorber, L., Zwaenepoel, K., Winne, K. D., Casteren, K. V., Augustus, E., Jacobs, J., Zhang, X. H., Galdermans, D., Droogh, E. D., Lefebure, A., et al. (2018) · Cancers · doi:10.3390/cancers10090290 · Cited by 21
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer
Facchinetti, F., Proto, C., Minari, R., Garassino, M. C., & Tiseo, M. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_16 · Cited by 22
Opportunities of circulating tumor DNA in lung cancer
Wu, T., Hsiue, E. H.-C., & Yang, J. C. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.07.002 · Cited by 20
Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations
Guo, K. X., Shao, C., Han, L., Liu, H., Ma, Z., Yang, Y., Feng, Y., Pan, M., Santarpía, M., Carmo‐Fonseca, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-530 · Cited by 21
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
Hsiue, E. H.-C., Lee, J., Lin, C., & Yang, J. C. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1248414 · Cited by 21
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
Zhu, Y.-J., Zhang, H.-B., Liu, Y., Zhang, F., Zhu, Y., Li, Y., Bai, J., Liu, L., Qu, Y., Qu, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14490 · Cited by 21
Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi, C., Zhang, M., Peng, X., Zhang, Y., Xu, C., & Zhou, Q. H. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1395701 · Cited by 21
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients
Garzón, M., Villatoro, S., Teixidó, C., Mayo, C., Martínez, A., Gil, M. D. L. L., Viteri, S., Morales-Espinosa, D., & Rosell, R. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.14 · Cited by 19
Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
Xu, Z., Hao, X., Wang, Q., Yang, K., Li, J., & Xing, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10676-x · Cited by 20
New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA
Duréndez-Saéz, E., Azkárate, A., Meri-Abad, M., Fariñas, S. C., Aguilar-Gallardo, C., Blasco, A., Lewintre, E. J., & Camps, C. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.112 · Cited by 19
Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction
Sung, J. S., Chong, H., Kwon, N., Kim, H. M., Lee, J. W., Kim, B., Lee, S. B., Park, C. W., Choi, J. Y., Chang, W. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22456 · Cited by 20
Liquid Biopsy in Solid Malignancy
Scarlotta, M., Şimşek, C., & Kim, A. K. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0237 · Cited by 22
The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
Lyu, M., Zhou, J. H., Kang, N., & Ying, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s195342 · Cited by 25
Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma.
Li, X., Wang, H., Li, T., Wang, L.-Z., Wu, X., Liu, J., Xu, Y.-H., & Wei, W. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.100516 · Cited by 19
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
Beau‐Faller, M., Pencreach, E., Leduc, C., Blons, H., Merlio, J., Bringuier, P., de Fraipont, F., Escande, F., Lemoine, A., Ouafik, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.013 · Cited by 21
Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy
Lv, P., Yang, S., Liu, W., Qin, H., Tang, X., Wu, F., Liu, Z., Gao, H., & Liu, X. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13216 · Cited by 20
Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic
Fernandes, G., Sousa, C., Reis, J. P., Martins, N. A., Moura, C. S., Guimarães, S., Justino, A., Pina, M. J., Magalhães, A., Queiroga, H., et al. (2021) · Cells · doi:10.3390/cells10081912 · Cited by 20
CLAmp‐seq: A Novel Amplicon‐Based NGS Assay with Concatemer Error Correction for Improved Detection of Actionable Mutations in Plasma cfDNA from Patients with NSCLC
Wang, L., Hu, X., Guo, Q., Huang, X., Lin, C., Chen, X., Li, M., Yao, Q., Zhou, Q., Wang, J., et al. (2019) · Small Methods · doi:10.1002/smtd.201900357 · Cited by 19
Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer
Yang, Y., Wang, J., Wang, J., Zhao, X., Zhang, T., Yang, Y., Pang, J., Xu, X., Xu, K., Xu, X., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216569 · Cited by 22
Urine test for EGFR analysis in patients with non-small cell lung cancer
Franovic, A., Raymond, V. M., Erlander, M. G., & Reckamp, K. L. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.144 · Cited by 20
The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future
Scilla, K. A., & Rolfo, C. D. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0653-2 · Cited by 20
Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment
Beagan, J. J., Bach, S., van Boerdonk, R. A. A., van Dijk, E., Thunnissen, E., van den Broek, D. A., Weiss, M. M., Geert Kazemier, M., Pegtel, D. M., Bahce, I., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.039 · Cited by 19
Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer
Fernandes, G., Martins, N. A., Moura, C. S., Guimarães, S., Reis, J. P., Justino, A., Pina, M. J., Magalhães, A., Queiroga, H., Machado, J. C., et al. (2021) · Cancers · doi:10.3390/cancers13112707 · Cited by 19
The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases
Bouhlel, L., Hofman, V., Maschi, C., Ilié, M., Allégra, M., Marquette, C., Audigier-Valette, C., Thariat, J., & Hofman, P. M. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1398089 · Cited by 19
Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients
Zhang, H., He, B., Cui, J., Zhao, M., & Zhang, Z. (2018) · Cancer Biomarkers · doi:10.3233/cbm-181511 · Cited by 19
EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management
Satapathy, S., Singh, V., Nambirajan, A., Malik, P. S., Tanwar, P., Mehta, A., Suryavanshi, M., Thulkar, S. P., Mohan, A., & Jain, D. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100722 · Cited by 18
ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma
Pérez-Barrios, C., Sánchez‐Herrero, E., García‐Simón, N., Barquín, M., Clemente, M. B., Provencio, M., & Romero, A. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1465 · Cited by 18
Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing–Based Comprehensive Tumor Profiling in Liquid Biopsy Samples
Harter, J., Buth, E., Johänning, J., Battke, F., Kopp, M., Zelba, H., Schulze, M., Ködding, J., & Biskup, S. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.10.001 · Cited by 19
Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients
Kato, K., Uchida, J., Kukita, Y., Kumagai, T., Nishino, K., Inoue, T., Kimura, M., Oba, S., & Imamura, F. (2016) · Scientific Reports · doi:10.1038/srep29093 · Cited by 19
A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics
Stanta, G., & Bonin, S. (2017) · Pathobiology · doi:10.1159/000477813 · Cited by 18
Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy
Kim, J., Park, D., Son, D., Nam, S. J., Kim, S. W., Jung, H. H., Kim, Y. J., Park, G., Park, W., Lee, J. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21198 · Cited by 19
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
Nigro, M. C., Marchese, P. V., Deiana, C., Casadio, C., Galvani, L., Federico, A. D., & Giglio, A. D. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s388047 · Cited by 19
Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)
Li, M., Hou, X., Zhou, C., Feng, W., Jiang, G., Long, H., Yang, S., Chen, J., Wang, N., Wang, K., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01216 · Cited by 17
Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
Siggillino, A., Ulivi, P., Pasini, L., Reda, M. S., Chiadini, E., Tofanetti, F. R., Baglivo, S., Metro, G., Crinò, L., Delmonte, A., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10121062 · Cited by 18
The Challenges of Precision Oncology Drug Development and Implementation
Hollingsworth, S. J., & Biankin, A. V. (2015) · Public Health Genomics · doi:10.1159/000441557 · Cited by 17
A digital PCR assay development to detect EGFR T790M mutation in NSCLC patients
Zhou, R., Cai, Y., Li, Z., Shen, S., Sha, M., Head, S. R., & Wang, Y. (2018) · Frontiers in Laboratory Medicine · doi:10.1016/j.flm.2018.08.002 · Cited by 17
Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual
Koessler, T., Addeo, A., & Nouspikel, T. P. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.12.004 · Cited by 17
Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer
Kasahara, N., Kenmotsu, H., Serizawa, M., Umehara, R., Ono, A., Hisamatsu, Y., Wakuda, K., Omori, S., Nakashima, K., Taira, T., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.001 · Cited by 16
Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer
Qu, L., Li, L., Zheng, X., Fu, H., Tang, C., Qin, H., Li, X., Wang, H., Li, J., Wang, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17416 · Cited by 16
The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer
Yu, K., Tsai, T.-H., Ho, C., Liao, W., Lin, C., Hsu, C., & Shih, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-24300-7 · Cited by 16
A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients
written on behalf of AME Lung Cancer Collaborative Group, Xu, H., Baidoo, A. A. H., Su, S., Ye, J., Chen, C., Xie, Y., Bertolaccini, L., Ismail, M., Ricciuti, B., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.03.10 · Cited by 16
Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study
Denis, M. G., Lafourcade, M.-P., Garff, G. L., Dayen, C., Falchero, L., Thomas, P. A., Locher, C., Oliviero, G., Licour, M., Reck, M., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.03.95 · Cited by 15
Non‑invasive detection of EGFR and TP53�mutations through the combination of plasma, urine and sputum in advanced non‑small cell lung cancer
Wu, Z., Yang, Z., Li, C., Zhao, W. M., Liang, Z., Dai, Y., Zeng, J., Zhu, Q., Miao, K., Cui, D., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10726 · Cited by 16
Towards Circulating-Tumor DNA-Based Precision Medicine
Hironaka‐Mitsuhashi, A., Calle, A. S., Ochiya, T., Takayama, S., & Suto, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091365 · Cited by 16
The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
Fernandes, M. G. O., Martins, N. A., Machado, J. C., Costa, J. L., & Hespanhol, V. P. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02382-0 · Cited by 16
A liquid biopsy in primary lung cancer
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2018) · Surgery Today · doi:10.1007/s00595-018-1659-2 · Cited by 17
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Park, C., Cho, H.-J., Choi, Y. D., Oh, I., & Kim, Y. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.459 · Cited by 15
Results of a worldwide external quality assessment of cfDNA testing in lung Cancer
Fairley, J. A., Cheetham, M. H., Patton, S. J., Rouleau, É., Denis, M. G., Dequeker, E. M. C., Schuuring, E. M. D., Casteren, K. V., Fenizia, F., Normanno, N., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09849-x · Cited by 15
Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment
Zhu, L., Zhang, S., Xun, Y., Jiang, Y., Xia, B., Chen, X., Wang, L., Jiang, H., & Ma, S. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0286-3 · Cited by 16
Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients
Wulandari, L., Soegiarto, G., Febriani, A., Wati, F. F., & Sahrun (2020) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-020-01046-1 · Cited by 15
Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy
Marcu, L. G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040222 · Cited by 15
Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
Ferreira, D., Miranda, J., Martins‐Lopes, P., Adega, F., & Chaves, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083815 · Cited by 15
Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
Buszka, K., Ntzifa, A., Owecka, B., Kamińska, P., Kolecka-Bednarczyk, A., Zabel, M., Nowicki, M. O., Lianidou, E. S., & Budna, J. (2022) · Cells · doi:10.3390/cells11182871 · Cited by 15
Transient appearance of circulating tumor DNA associated with de novo treatment
Kato, K., Uchida, J., Kukita, Y., Kumagai, T., Nishino, K., Inoue, T., Kimura, M., & Imamura, F. (2016) · Scientific Reports · doi:10.1038/srep38639 · Cited by 15
Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
Pasquale, R., Forgione, L., Roma, C., Fenizia, F., Bergantino, F., Rachiglio, A. M., Luca, A. D., Gallo, M., Maiello, M. R., Palumbo, G., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.01 · Cited by 14
Profiling Non–Small Cell Lung Cancer: From Tumor to Blood
Tsui, D. W. Y., & Berger, M. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2514 · Cited by 14
Possible application of circulating free tumor DNA in non-small cell lung cancer patients
Karachaliou, N., Sosa, A. E., Molina‐Vila, M. Á., Ruiz, M. C., & Rosell, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.59 · Cited by 14
Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-analysis
Mlika, M., Dziri, C., Zorgati, M. M., Khelil, M. B., & Mezni, F. E. (2018) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x14666180430144452 · Cited by 14
Detection of plasmaEGFRmutations for personalized treatment of lung cancer patients without pathologic diagnosis
Deng, Q., Fang, Q., Sun, H., Singh, A. P., Alexander, M., Li, S., Cheng, H., & Zhou, S. (2020) · Cancer Medicine · doi:10.1002/cam4.2869 · Cited by 14
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment
Buttitta, F., Felicioni, L., Lorito, A. D., Cortellini, A., Irtelli, L., Brocco, D., Marino, P. D., Traisci, D., D’Ostilio, N., Paolo, A. D., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27517 · Cited by 14
The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer
Akhoundova, D., Mosquera, J., Musmann, L. E., Britschgi, C., Rütsche, C., Rechsteiner, M., Nadal, E., Campelo, M. R. G., & Fontecedro, A. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113674 · Cited by 14
Analyzing epidermal growth factor receptor mutation status changes in advanced non‐small‐cell lung cancer at different sampling time‐points of blood within one day
Wang, J., Bai, H., Hong, C., Wang, J., & Mei, T. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12443 · Cited by 16
ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting
Zhang, S., Zhu, L., Chen, X., Zhang, X., Chen, E., Fang, H., Feng, Y., Li, Y., Wang, X., Jiang, Z., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.166 · Cited by 13
Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer
Cecchini, M. J., & Yi, E. S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.20 · Cited by 15
The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era
Costa, J., Membrino, A., Zanchetta, C., Rizzato, S., Cortiula, F., Rossetto, C., Pelizzari, G., Aprile, G., & Macerelli, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413669 · Cited by 13
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13
Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications
Shah, U. J., Alsulimani, A., Ahmad, F., Mathkor, D. M., Alsaieedi, A., Harakeh, S., Nasiruddin, M., & Haque, S. (2022) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2022.2108994 · Cited by 14
Liquid Biopsy and NSCLC
Trombetta, D., Sparaneo, A., Fabrizio, F. P., & Muscarella, L. A. (2016) · Lung Cancer Management · doi:10.2217/lmt-2016-0006 · Cited by 14
Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms
Proto, C., Russo, G. L., Corrao, G., Ganzinelli, M., Facchinetti, F., Minari, R., Tiseo, M., & Garassino, M. C. (2017) · Tumori Journal · doi:10.5301/tj.5000663 · Cited by 14
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non–Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor
Goldman, J. W., Karlovich, C., Sequist, L. V. D., Melnikova, V., Franovic, A., Gadgeel, S. M., Reckamp, K. L., Camidge, D. R., Pérol, M., Ou, S. I., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00116 · Cited by 13
CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation
Zhao, J., Dinkel, J., Warth, A., Penzel, R., Reinmuth, N., Schnabel, P. A., Muley, T., Meister, M. A., Zabeck, H., Steins, M. B., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182741 · Cited by 13
EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method
Yoshida, H., Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Tsuji, T., Nomizo, T., Funazo, T. Y., Yasuda, Y., & Hirai, T. (2017) · Anticancer Research · doi:10.21873/anticanres.11623 · Cited by 12
Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
Nordgård, O., Forthun, R. B., Lapin, M., Grønberg, B. H., Kalland, K., Kopperud, R. K., Thomsen, L. C. V., Tjensvoll, K., Gilje, B., Gjertsen, B. T., et al. (2021) · Cancers · doi:10.3390/cancers13081861 · Cited by 12
CONCORDANCE
Prabhash, K., Biswas, B., Khurana, S., Batra, U., Biswas, G., Advani, S. H., Mohapatra, P. N., Rajappa, S. J., Sharma, A. K., Patil, S., et al. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_438_21 · Cited by 12

Authors: Douillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., Cole, R., McWalter, G., Walker, J., Dearden, S., Webster, A., Milenkova, T., & McCormack, R.
Affiliations: Iuliu Hațieganu University of Medicine and Pharmacy (RO)
Országos Korányi Tbc és Pulmonológiai Intézet (HU)
Hospital Regional Universitario de Málaga (ES)
AstraZeneca (United Kingdom) (GB)
Corresponding author: Douillard, Jean-Yves
ORCID: Douillard, Jean-Yves
Ostoros, Gyula
Cobo, Manuel
Ciuleanu, Tudor
Cole, Rebecca
Walker, Jill
Dearden, Simon
Milenkova, Tsveta
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2014-09
Volume: 9
Issue: 9
Pages: 1345-1353
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0000000000000263
PMC: PMC4224589
OpenAlex: W1978285367
Cited by: 448
References: 28
Citations by year: 2026: 2 · 2025: 7 · 2024: 8 · 2023: 16 · 2022: 20 · 2021: 37 · 2020: 44 · 2019: 69 · 2018: 70 · 2017: 72 · 2016: 63 · 2015: 38 · 2014: 2
FWCI: 46.71
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 438 d)
Locations: Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, EGFR mutation, non-small cell lung cancer, circulating tumor DNA, liquid biopsy, plasma DNA, tumor mutation status, treatment response, sensitivity and specificity, first-line therapy, Caucasian patients, EGFR tyrosine kinase inhibitors, objective response rate, progression-free survival, overall survival
MeSH terms: Gefitinib, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, DNA, Neoplasm, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prospective Studies, Quinazolines, Single-Blind Method, Treatment Outcome, Disease-Free Survival, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks